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Background: Diet has a significant relationship with the risk of coronary heart disease (CHD). Traditionally the effect
of diet on CHD was measured with the biomarker for low-density lipoprotein (LDL) cholesterol. However, LDL is not
the only or even the most important biomarker for CHD risk. A suitably integrated view of the mechanism by which
diet influences the detailed CHD pathogenetic pathways is therefore needed in order to better understand CHD risk
factors and help with better holistic CHD prevention and treatment decisions.
Methods: A systematic review of the existing literature was conducted. From this an integrated CHD pathogenetic
pathway system was constructed. CHD biomarkers, which are found on these pathways, are the only measurable
data to link diet with these CHD pathways. They were thus used to simplify the link between diet and the CHD
mechanism. Data were systematically analysed from 294 cohort studies of CHD biomarkers constituting 1 187 350
patients.
Results and discussion: The resulting integrated analysis provides insight into the higher-order interactions
underlying CHD and high-glycemic load (HGL) diets. A novel “connection graph” illustrates the measurable
relationship between HGL diets and the relative risks attributed to the important CHD serological biomarkers.
The “connection graph” vividly shows that HGL diets not only influence the lipid and metabolic biomarkers,
but also the inflammation, coagulation and vascular function biomarkers in an important way.
Conclusion: A focus primarily on the low density lipoprotein cholesterol biomarker for CHD risk has led to
the traditional guidelines of CHD dietary recommendations. This has however inadvertently led to HGL diets.
The influence of HGL diets on the other CHD biomarkers is not always fully appreciated. Thus, new diets or
other interventions which address the full integrated CHD impact, as shown in this paper, are required.
Keywords: High glycemic load, Coronary heart disease, BiomarkersBackground
Coronary heart disease (CHD) is the largest cause of death
globally [1]. Cholesterol is commonly assumed to be a cru-
cial element of CHD [2]. Therefore dietary recommenda-
tions have traditionally focused on the reduction of
saturated fatty acids [3]. This has led to the adoption of
low-fat, high carbohydrate diets [4]. However, such high-
glycemic load (HGL) diets have been shown to increase
the relative risk for CHD [3,5].
Forty percent of CHD deaths occur in men and women
who have cholesterol levels lower than the average for the* Correspondence: mjmathews@rems2.com
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unless otherwise stated.general population [6]. The focus on a single biomarker
may thus be oversimplified.
But how does a HGL diet influence all the CHD patho-
genetic pathways? The authors could not find a study
which integrated all the CHD pathways activated by a
HGL diet in order to give insight at a glance. This paper
thus investigates the interconnectivity of the effects of
HGL diets with CHD pathogenetic pathways. We then
use CHD biomarkers, which measure the CHD risk of a
pathway, to simplify the integrative CHD model.
We can thus investigate all the effects of a HGL diet
on CHD risk, as opposed to only the effect of the path-
ways quantified by one biomarker, namely low-density
lipoprotein (LDL) cholesterol.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Search criteria
We searched PubMed, Science Direct, Ebsco Host, and
Google Scholar for publications with “coronary heart
disease“ or “coronary artery disease” or “cardiovascular
disease” or “CHD” as a keyword and combinations with
“high glycemic load diets”, “relative risk prediction”, “net-
work analysis”, “pathway analysis”, “interconnections”,
“systems biology”, “pathogenesis”, “biomarkers”, “conven-
tional biomarkers”, “drugs”, “therapeutics”, pharmacothera-
peutics”, “hypercoagulability”, “hypercholesterolaemia”,
“hyperglycaemia”, “hyperinsulinaemia”, “inflammation”,
and “hypertension” in the title of the study.
We also searched all major relevant specialty journals
in the areas of cardiology, nutrition, endocrinology, psycho-
neuroendocrinology, systems biology, physiology, CHD, the
metabolic syndrome and diabetes, such as Circulation;
Journal of the American College of Cardiology; Arterioscler-
osis, Thrombosis and Vascular Biology; The Lancet; New
England Journal of Medicine; American Journal of Medi-
cine; Nature Medicine; Diabetes Care; Journal of Clinical
Endocrinology and Metabolism; American Journal of Clin-
ical Nutrition; Preventive Medicine; Molecular Psychology;
and Journal of Physiology for similar or related articles.
Furthermore, we selected PubMed and Google Scholar
for meta-analyses with keywords “coronary heart disease”
or “coronary artery disease” or “cardiovascular disease” or
“CHD”. We also reviewed articles referenced in primary
sources and their relevant citations. However, unless cited
more than 50 times, we included only articles published
after 1998 as these contained the most relevant data.
Study selection
Only articles using the following risk measures were in-
cluded: relative risk (RR), odds ratio (OR), or hazard ratio
(HR). It was not the intention of this study to conduct
individual meta-analyses of the individual biomarkers or
lifestyle effects and thus the most recent meta-analysis of
each biomarker was used for the risk data. Where no
meta-analysis for CHD risk was available for a specific
biomarker or lifestyle effect a single high quality represen-
tative study was used.
Only the trends from each meta-analysis that was ad-
justed for the most confounding variables was used and
only where sufficient information was available on that
trend. This was done so that the effects of most of the
potential confounders could be adjusted for. This may,
however, have increased the heterogeneity between stud-
ies, as not all studies adjusted for the same confounders.
CHD was classified as the incidence of atherosclerosis,
coronary artery disease, or myocardial infarction. Where
results were given for cardiovascular disease these were
interpreted as CHD only in scenarios where the effect of
stroke could be accounted for or results were presentedseparately. Biomarkers were only considered if they were
associated with an increased or decreased risk of CHD.
In a general sense we characterised two different aspects
that had an effect on CHD risk from the systems based
view of CHD by using RR data. These aspects were the
lifestyle effects and the risk associated with increased
levels of certain biomarkers. The lifestyle effects were con-
sidered as effect versus control. In other words, the RR
was calculated for the CHD incidence of a lifestyle versus
a control or placebo group. For the biomarkers, however,
a different approach had to be used due to the differing
levels of markers which are possible in vivo.
The RR for HGL diet effects was retrieved from a meta-
analysis based on prospective population based studies.
The RR data for the biomarkers were also retrieved from
meta-analyses based largely on prospective population
based studies.
The RR for changes in biomarkers were, where pos-
sible, extracted from the most recent meta-analysis con-
ducted on the specific biomarker. If no meta-analysis
was available, a suitable high quality study was included.
In order to limit errors in comparisons between bio-
markers only RR given per increase of 1-standard devi-
ation (SD) in the biomarker level was included. The
standardisation of RR to RR per 1-SD prohibits the mis-
representation of risk due to the selection of extreme ex-
posure contrasts [7].
Data extraction
The following data were extracted from the studies:
journal citation; number of cases per lifestyle study for
OR, RR and HR; total number of persons, including gen-
der, per study; characterisation and severity of lifestyle;
type/intensity of CHD; whether the risk was measured
in RR, OR or HR; the risk per lifestyle study, and the
95% confidence intervals per lifestyle study.
Data analysis
Heterogeneity between studies was inevitable due to the
large quantity of meta-analyses considered. Each under-
lying meta-analysis reported individually on the hetero-
geneity in their analysis. However, these effects were not
so large as to discount the effects observed.
The individual meta-analyses also had detailed accounts
of differences between studies and subgroup analyses.
However, these aspects are not further elaborated on in
this study as they were used as a measure of validity in the
study inclusion process. The individual studies selected
unfortunately represent only the risk associated with the
cohort studied and cannot be accurately extrapolated to
other populations without further research.
OR and HR were converted to RR using the approach
outlined by Zou [8]. It must however be noted that some
of the RR values in this article differ from convention.
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of the traditional relative risk. Traditionally, if one plots
an RR = 3 and RR = 0.33, respectively, the one does not
‘look’ three times worse and the other three times better
than the normal RR = 1. The reason is that the scales for
the positive and negative effects are not numerically
similar. A graph of ‘good’ and ‘bad’ RR can therefore be
deceptive for the untrained person, e.g., a patient.
This article rather uses the method that the conven-
tional RR = 3 is three times worse than the normal RR = 1.
While the conventional RR = 0.33 means that the patient’s
position is three times better than the normal RR = 1.
Thus, in summary: a conventional RR = 3 is presented
as per normal, as a 3-fold increase in risk and a con-
ventional RR = 0.33 is presented as a 3-fold decrease
in risk (1/0.33 = 3).
Results
Integrated model
The integrated model in Figure 1, which we developed,
schematically illustrates the complexity of CHD. (A
more detailed discussion of Figure 1 is given in Section
“Pathogenetic effects of high glycemic load diets”). It is
however important to realize that CHD involves inputs
from hundreds of gene expressions and a number of tis-
sues. Thus, analysing the individual components of the
system would not be sufficient, as it is important to know
how these components interact with each other [9]. For
instance, genetic and lifestyle factors influence clinical
traits by perturbing molecular networks [10]. A high-level
systems-based view of CHD therefore has the potential to
interrogate these molecular phenotypes and identify the
patterns associated with the disease.
Pathways can be tracked from a chosen lifestyle effect
to a hallmark of CHD if the two states are connected by
the pathogenesis of the disorder. The pathways are
therefore a visual representation of previously published
knowledge integrated here.
The pathogenetic pathways of interest for this review
were only those between HGL diets (“Food”) and CHD.
The effects of other lifestyle effects (e.g. moderate alco-
hol consumption, moderate intensity exercise, smoking,
oral health, chronic stress, depression, insomnia and
sleep apnoea) are not considered here.
The lifestyle effect of “Food” (Figure 1) was regarded as
HGL diets (daily mean GL ≥ 142). “Tissue” in Figure 1 in-
dicates the organ or type of tissue which is affected by a
pathogenetic pathway or trait. “Pathogenesis” in Figure 1
indicates the pathological pathways of the disorder.
Salient serological biomarkers (shown in Figure 1 as )
and pharmacotherapeutics (shown in Figure 1 as )
that act on the pathways are also indicated in Figure 1.
These pathogenetic pathways also lead to certain traits
(e.g. insulin resistance) that lead to five pathophysiologicalend-states, which we designate as “hallmarks of CHD”, namely
hypercoagulability, hypercholesterolaemia, hyperglycaemia/
hyperinsulinaemia, an inflammatory state, and hypertension.
The formulation of this conceptual model required the
consultation of numerous publications. The journal refer-
ences which were used to describe the main pathogenetic
pathways in the model are given in Table 1. It is however
not the purpose of this review to describe in detail all
these pathways. The aim is merely to simplify Figure 1 to
show only the pathways relevant to HGL diets.
Despite the rich body of existing knowledge pertaining
to CHD pathogenesis, lifestyle effects, and pharmacother-
apeutics [9,10,45,101], a suitably integrated high-level con-
ceptual model of CHD could not be found. A high-level
model that consolidates the effects of HGL diets on rela-
tive risk of CHD and CHD biomarkers was therefore
developed. This model could thus help elucidate the
higher-order interactions underlying CHD [9] and pro-
vide new insights into dietary interventions.
Pathogenetic effects of high-glycemic load diets
Figure 1 indicates all possible pathogenetic pathways be-
tween the various lifestyle effects and CHD. In the present
review only the CHD effects of HGL diets are appraised.
The pathogenetic pathways which are activated by HGL
diets are elucidated in Table 2. It is important to note that
not all the pathogenetic pathways indicated in Figure 1
will be relevant in all patients, and all the pathways may
not be active simultaneously.
Figure 1, Pathway: 2-17-14-blood glucose-55-hyperglycaemia
shows how HGL diets are connected to hyperglycaemia
through the increase of blood glucose due to carbo-
hydrate consumption [127]. The resulting state of hyper-
glycaemia and concomitant hyperinsulinaemia are both
CHD hallmarks in non-diabetic patients [128]. (Figure 1,
Pathway: 2-17-14-blood glucose-55-hyperglycaemia).
The hyperglycaemia that result from HGL diets can also
lead to an increase in the PI3K-to-MAPK ratio, through
inhibition of the phosphatidylinositol 3-kinase (PI3K) in-
sulin signalling pathway or the stimulation of the MAPK
pathway [89]. This in turn increases insulin resistance
[129]. (Figure 1, Pathway: 2-17-14-blood glucose-54-PI3K:
MAPK-69-insulin resistance).
Decreased insulin sensitivity, due to insulin resist-
ance, has been associated with increases in the serum
levels of platelet factors, such as fibrinogen [130] and
von Willebrand factor [131], and thus increased po-
tential for hypercoagulability which is a CHD hallmark
[132,133]. (Figure 1, Pathway: 2-17-14- blood glucose-54-
PI3K:MAPK-69-insulin resistance-72-platelet factors-73-
hypercoagulability).
Further, decreased adiponectin levels can result from
increased adipose tissue levels stemming from excessive
dietary intake due to HGL diets [86]. Decreases in plasma
Figure 1 Conceptual model of general lifestyle effects, salient CHD pathogenetic pathways and CHD hallmarks. The affective pathway of
pharmacotherapeutics, blue boxes, is shown in Figure 1, and salient serological biomarkers are indicated by the icon. The blunted blue arrows
denote antagonise or inhibit and pointed blue arrows denote up-regulate or facilitate. HDL denotes high-density lipoprotein; LDL, low-density lipoprotein;
oxLDL, oxidised LDL; FFA, free fatty acids; TMAO, an oxidation product of trimethylamine (TMA); NLRP3, Inflammasome responsible for activation of
inflammatory processes as well as epithelial cell regeneration and microflora; Hs, homocysteine; IGF-1, insulin-like growth factor-1; TNF-α , tumour
necrosis factor-α; IL, interleukin; NO, nitric oxide; NO-NSAIDs, combinational NO-non-steroidal anti-inflammatory drug; SSRI, serotonin reuptake
inhibitors; ROS, reactive oxygen species; NFκβ, nuclear factor-κβ; SMC, smooth muscle cell; HbA1c, glycosylated haemoglobin A1c; P. gingivalis, Porphyromonas
gingivalis; vWF, von Willebrand factor; PDGF, platelet-derived growth factor; MIF, macrophage migration inhibitory factor; SCD-40, recombinant human
sCD40 ligand; MPO, myeloperoxidase; MMP, matrix metalloproteinase; VCAM, vascular cell adhesion molecule; ICAM, intracellular adhesion
molecule; CRP, C-reactive protein; PAI, plasminogen activator inhibitor; TF, tissue factor, MCP, monocyte chemoattractant protein; BDNF, brain-derived
neurotrophic factor; PI3K, phosphatidylinositol 3-kinase; MAPK, mitogen-activated protein (MAP) kinase; RANKL, receptor activator of nuclear factor
kappa-beta ligand; OPG, osteoprotegerin; GCF, gingival crevicular fluid; D-dimer, fibrin degradation product D; BNP, B-type natriuretic peptide; ACE,
angiotensin-converting-enzyme; COX, cyclooxygenase; β-blocker, beta-adrenergic antagonists.
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sitivity by decreasing muscle fat oxidation [134] and sub-
sequently cause increased vasodilation [86] which is a
hallmark of CHD. Additionally, it is possible for decreases
in adiponectin levels to increase those of intramyocelular
triacylglycerol which are correlated to insulin resistance
[135,136]. (Figure 1, Pathway: 2-17-blood glucose-54-19-
adiponectin-39-insulin resistance-vasodilation).Figure 1 also shows why an insulin-resistant state may
be pro-inflammatory, with the expression of the inflamma-
tory mediator TNF-α by adipose tissue being a core aspect
associated with plasma insulin [134]. Additionally, adipose
tissue has been shown to express other pro-inflammatory
mediators, including C-reactive protein (CRP). Macro-
phages residing in the adipose tissue may also be a source
of pro-inflammatory factors by modulating the secretory
Table 1 Pathogenetic pathways (in Figure 1) and cited works
Pathway Refs. Pathway Refs. Pathway Refs. Pathway Refs. Pathway Refs. Pathway Refs.
1 [11,12] 2 [13-17] 3 a,b,c [18-20] 4 a,b [21-23] 5 [24-26] 6 [27-29]
7 a,b [30-35] 8 a,b [36-38] 9 [39] 10 [40,41-44] 11 [44,45] 12 [44]
13 [15-17] 14 [45-53] 15 [52-54] 16 [36-38] 17 [46-53] 18 [23,55-57]
19 [54,55] 20 [36-38] 21 [45,57-63] 22 [57] 23 [64-68] 24 [69-71]
25 [36-38] 26 [69-74] 27 [28,29,75-87] 28 [88-92] 29 [44,93] 30 [40,41-45]
31 [40,41-45] 32 [44] 33 [44] 34 [45,54-57] 35 [36-38] 36 [45,54-57]
37 [45,54-57] 38 [61,86,94-98] 39 [54,55] 40 [36-38] 41 [60,61,98] 42 [60,92]
43 [24,60,61,64-68] 44 [69-71] 45 [27,79,81] 46 [27,79,81] 47 [27,79,81] 48 [27,79,81]
49 [88-90,99] 50 [44,95,100] 51 [9,10,44,45,93,94,100-104] 52 [15,16] 53 [45-53] 54 [45-53]
55 [45-53,105-110] 56 [45,54-57] 57 [45,54-57,93,111-114] 58 [45,54-57,93] 59 [82-85] 60 [82-85]
61 [82-85] 62 [24,65] 63 [64-67] 64 [24,25] 65 [24,25,66] 66 [36-38]
67 [36-38] 68 [54-57] 69 [88] 70 [88-90] 71 [44,88-90,93,115,116] 72 [44,88-90,93,115,116]
73 [40,45,92] 74 [40,45,92] 75 [40,63,92,105,112] 76 [45,60,61] 77 [60,105] 78 [60,105]
79 [40,45,60,105] 80 [40,45,60,105] 81 [40,60,105] 82 [40,88,94] 83 [107-110] 84 [60]
85 [45,94,101,113,114] 86 [45,94] 87 [94] 88 [44,94,112,115,116] 89 [44,94,112,115,116] 90 [40,105,112]
91 [69-71] 92 [40,44,102] 93 [69,70] 94 [117-120] 95 [121-124] 96 [121-124]
97 [44] 98 [40,60,94,105] 99 [44] 100 [94] 101 [88-90] 102 [44,46,49,88,94,102]
103 [44,45,60,62] 104 [44,45,94,102,112] 105 [44,45,60,62,125,126] 106 [44,45,94,102,112]















Table 2 Putative effects of high glycemic load diets and salient CHD pathogenetic pathways
Lifestyle Pathways, and pathway numbers corresponding to those in Figure 2 Refs.
High- GL
diets
a. 2-↑17-14-↑ blood glucose-55-↑ hyperglycaemia a. [13,57,103]
b. 2-↑17-14-↑ blood glucose-54-19-↓ adiponectin-38-↑ TNFα-56-12-↑ LDL-33-↑ oxLDL-51-↑ hypercholesterolaemia b. [13,57,103]
c. 2-↑17-14-↑blood glucose-54-↑ PI3K:MAPK-69-↑ insulin resistance-70-↑ angiotensin II-89-↑
hypertension-100-↑ROS-85-↑ inflammatory state
c. [13,57,95,105]
d. 2-↑17-14-↑ blood glucose-54-↑ PI3K:MAPK-69-↑ insulin resistance-70-↑ angiotensin II-88-50-↑ TNFα-41-↑
inflammatory state
d. [101]
e. 2-↑17-14-↑ blood glucose-54-↑ PI3K:MAPK-69-↑ insulin resistance-70-↑ angiotensin II-89-↑ SMC proliferation e. [62]
f. 2-↑17-14-↑ blood glucose-54-↑ PI3K:MAPK-69-↑ insulin resistance-70-↑ angiotensin II-89-↓ IGF1-84-↑ SMC proliferation f. [121-123]
g. 2-↑17-14-↑ blood glucose-54-↑ PI3K:MAPK-69-↑ insulin resistance-70-↑ angiotensin II-89-↑ VCAM1/MCP1-73-↑
hypercoagulability
g. [60]
h. 2-↑17-14-↑ blood glucose-54-↑ PI3K:MAPK-69-↑ insulin resistance-72-↑ platelet factors-73-↑ hypercoagulability h. [40,48]
i. 2-↑17-14-↑ blood glucose-54-19-↓ adiponectin-38-↑ TNFα-41-↑ P. gingivalis-43-↑ periodontitis-64-↑
platelet factors-73-↑ hypercoagulability
i. [27,40,48,66]
j. 2-↑17-14-↑ blood glucose-54-19-↓ adiponectin-39-↑ insulin resistance j. [101]
k. 2-↑17-14-↑ blood glucose-54-19-↓ adiponectin-39-↑ SMC proliferation k. [94]
l. 2-↑17-14-↑ blood glucose-54-↑ PI3K:MAPK-69-↑ insulin resistance-72-↑ hyperglycaemia l. [88,89]
m. 2-↑17-14-↑ blood glucose-55-↑ SMC proliferation m. [103]
n. 2-↑17-14-↑ blood glucose-53-↑ NO depletion-57-↑ SMC proliferation n. [28,89,105,111]
o. 2-↑17-14-↑ blood glucose-53-↑ NO depletion-57-↓ vasodilation o. [28,97,103,105]
p. 2-↑17-14-↑ blood glucose-54-60-↑insulin resistance-72-↓ vasodilation p. [101,103]
q. 2-↑17-14-↑ blood glucose-54-↑angiotensin II-89-↑hypertension-100-↑ROS-85-↑inflammatory state q. [28,93,103]
r. 2-↑15-34-12-↑ LDL-33-↑ oxLDL-51- ↑ hypercholesterolaemia r. [14]
s. 2-↑15-34-13-↑ TMAO/NLRP3-52-macrophage-78-foam cell-↑ SMC proliferation s. [15-17]
t. 2-↑15-34-13-↑ TMAO/NLRP3-52-macrophage-51-↑ hypercholesterolaemia t. [15-17]
u. 2-↑15-34-13-↑ TMAO/NLRP3-52-macrophage-77-↑ inflammatory state u. [15-17]
↑denotes upregulation/increase, ↓denotes downregulation/decrease, x-y-z indicates pathway connecting x to y to z. HDL, high-density lipoprotein; LDL, low-density
lipoprotein; oxLDL, oxidised LDL; FFA, free fatty acids; TNFα, tumour necrosis factor-α; IL6, interleukin-6; NO, nitric oxide; ROS, reactive oxygen species; BDNF,
brain-derived neurotrophic factor; OSA, obstructive sleep apnoea; SMC, smooth muscle cell; P. gingivalis, Porphyromonas gingivalis; PI3K, phosphatidylinositol
3-kinase; MAPK, mitogen-activated protein (MAP) kinase; PI3K:MAPK, ratio of PI3K to MAPK; IGF 1, insulin-like growth factor-1; VCAM 1, vascular cell adhesion molecule-1;
MCP 1, monocyte chemoattractant protein-1.
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15-34-13-TMAO/NLRP3-52-macrophage-77-inflammatory
state).
HGL diets can also lead to the accumulation of vis-
ceral fat, reduced lipoprotein lipase activity and reduced
clearance of triglycerides. This leads to increased LDL
levels, decreased high-density lipoprotein (HDL) levels, and
increased LDL-to-HDL ratios [138], and eventually to
hypercholesterolaemia [128] which contributes significantly
to atherogenecity, leading to CHD [139]. (Figure 1, Pathway:
2-15-34-12-LDL-33-oxLDL-51-hypercholesterolaemia).
The CHD hallmark hypertension is directly correlated
with visceral fat mass [140]. Hypertension may also be
mediated through increased vascular and sympathetic
tone created by reduced bioavailability of nitric oxide
(NO) because of oxidative stress, and increased expression
of angiotensinogen by adipose tissue leading to an activa-
tion of the renin-angiotensin system [141,142]. (Figure 1,
Pathway: 2-17-14-blood glucose-54-angiotensin II-89-
hypertension).From the above high-level model, it is apparent that
HGL diets have multiple effects on the pathogenetic
mechanism of CHD. Therefore, it can be seen that with
greater activation of the pathways connected to the hall-
marks of CHD, a patient’s risk of CHD is further amplified.
Thus, an integrated multi-faceted approach to therapeutics
and lifestyle factors is necessary.
Biomarkers of coronary heart disease
The integrated model that was developed is a high-level
conceptual model, from which the interconnectedness of
CHD is immediately apparent (Figure 1). The model is
however complicated, thus a novel approach was used to
simplify it with regards to the consumption of a HGL
diet. In order to simplify the integrated model, serological
biomarkers (which can be easily measured) were used
to link the effect of HGL diet to the corresponding CHD
pathways.
Biomarkers are used as indicators of an underlying disorder
or pathogenetic pathway, such as systemic inflammation that
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[60,61,143]. The measurement of specific biomarkers there-
fore enables the prediction of the relative risk for CHD as-
sociated with these biomarkers [44]. As it is possible to
accurately measure certain serum biomarker levels, they can
also be used as patient-specific links to pathogenetic, lifestyle
(e.g. diet) or pharmacotherapeutic (e.g. α-glucosidase inhibi-
tors) factors. In essence, the biomarkers can be used to in-
dicate the activation of underlying pathogenetic pathways
of the disorder. The biomarkers associated with different
pathways are indicated in Figure 1 as .
Important CHD biomarkers which have been noted to
change with chronic consumption of HGL diets are hyper-
glycaemia as represented by changes in the glycated
haemoglobin levels [144] and hyperinsulinaemia as repre-
sented by increased serum insulin levels [145]. Further,
additional biomarkers of interest would be the traditional
cholesterol levels of LDL and HDL, which have both been
noted to be affected by excessive consumption of HGL
diets [145].
The authors could however not find a published study
where all the important serum biomarkers were compared
in order to show their relative importance regarding CHD
risk prediction in terms of relative risk. We therefore
attempted this in Table 3 and the results thereof are pre-
sented graphically in Figure 2.
Table 3 presents the relative risk data from 294 cohort
studies comprising 1 161 560 subjects. The results from
the studies were thus interpreted and the averaged relative
risks (with standard error (I) and study size (N)) were used
to populate Figure 2. Figure 2 visually compares the RR
associated with serological biomarkers per 1-standard de-
viation increase in said biomarker.
The main outcome from the relative risk comparison
in Figure 2 is that it allows one to compare the relative
risk of CHD associated with changes in certain bio-
markers. From the figure, it is clear that adverse changes
in certain biomarkers, such as ApoB, present a much
greater risk than the generally considered LDL cholesterol
(Shown in Figure 2 in red). Additionally, glycated haemo-
globin A1c (HbA1c), an easy-to-measure biomarker that is
well correlated with HGL diets [144], is associated with a
large increased risk. This type of consideration thus al-
ludes to biomarkers such as ApoB and insulin resistance
that are potentially more important for lifestyle and
pharmaceutical interventions.
Although the numerical values of relative risk presented
in this study are based on large, clustered clinical trials,
and thus give a good idea of average effects, it is acknowl-
edged that individual patients will have very specific CHD
profiles. However, Figure 1 is still relevant to everyone and
should thus provide general insight into relevant risk fac-
tors. Therefore, Figure 1 could inter alia reveal further
pathways still available for biomarker and drug discovery.Effects of high-glycemic load diets
The pathogenesis of different lifestyle effects are illus-
trated in Figure 1 and the specific paths regulated by
HGL diets are detailed in Table 2. It is therefore possible
to quantify the effects of HGL diets on the RR of CHD
using Figure 1 as a model for the pathogenesis of CHD.
By considering the pathogenesis of HGL diets, the path-
ways activated thereby are elucidated in Figure 1. Cer-
tain pathways might be quantified by the measurement
of specific biomarkers (shown as in Figure 1).
The effects of HGL diets on CHD are further charac-
terised by the ‘connection graph’ in Figure 3. The ‘connec-
tion graph’ is a simplification of the pathogenesis of CHD
presented in Figure 1. Within this graph none of the
underlying pathogenesis is neglected, but only the CHD
biomarkers affected by HGL diets are indicated. The path-
ways, from Figure 1, through which the consumption
of HGL diets effect the biomarkers are shown on the
connections.
To make further deductions from the ‘connection graph’
the biomarkers have been sorted into classes in terms of
their clinical effect. The classes are renal function, necro-
sis, coagulation, oxidative stress, vascular function, lipids,
metabolic function and inflammation. The ‘connection
graph’ therefore allows easy visual recognition of the ef-
fects of different lifestyle factors, in this case HGL diets on
the biomarkers of CHD.
The pathogenetic pathways (from Figure 1) are superim-
posed on the connecting lines in Figure 3. Therefore, in-
creasing line thickness indicates a connection with greater
pathogenetic effect (as quantified by the biomarker’s rela-
tive risk prediction of CHD). For example, the relative risk
of CHD is relatively low when considering leptin, thus the
connection line between HGL diets and leptin is thin.
From the connection graph, it is clear that there are many
connections between HGL diets and the biomarkers of
CHD. Firstly, it is rather evident that chronic consumption
of a HGL diet would serve to induce chronic hypergly-
caemia [165]. This chronic hyperglycaemia will be evident
in increased HbA1c levels [166] which predicts an increased
RR of CHD [159].
Since hyperglycaemia stimulates insulin secretion [167],
chronic hyperglycaemia could also serve to increase insu-
lin resistance, by the over-production of insulin [131]. In-
sulin resistance, which predicts an increased RR of CHD
[164], is associated with hyperinsulinaemia [168].
The metabolic marker adiponectin (Figure 3) is also
linked to HGL diets, through increased obesity and vis-
ceral adiposity possible from HGL diets [169] which are
known to reduce the plasma levels of adiponectin [170].
Increased fibrinogen levels, a coagulation biomarker in
Figure 3, are postulated to be caused by increased insulin
resistance [130], however this pathogenesis is not fully
understood. It is however clear that there is some causal
Table 3 Salient serological and functional biomarkers of CHD, and prospective ones
Biomarker (class and salient examples) Prediction of CHD relative risk (95% CI) Size of studies (N = number of trials,
n = number of patients)
Ref.
Lipid-related markers:
Triglycerides 0.99 (0.94-1.05) (N = 68, n = 302 430) [146]
LDL 1.25 (1.18-1.33) (N = 15, n = 233 455) [147]
HDL 0.78 (0.74-0.82) (N = 68, n = 302 430) [146]
ApoB 1.43 (1.35-1.51) (N = 15, n = 233 455) [147]
Leptin 1.04 (0.92-1.17) (n = 1 832) [148]
Inflammation markers:
hsCRP 1.20 (1.18-1.22) (N = 38, n = 166 596) [149]
IL-6 1.25 (1.19-1.32) (N = 25, n = 42 123) [150]
TNF-α 1.17 (1.09-1.25) (N = 7, n = 6 107) [150]
GDF-15 1.40 (1.10-1.80) (n = 1 740) [151]
OPG 1.41 (1.33-1.57) (n = 5 863) [152]
Marker of oxidative stress:
MPO 1.17 (1.06-1.30) (n = 2 861) [153]
Marker of vascular function and neurohormonal activity:
BNP 1.42 (1.24-1.63) (N = 40, n = 87 474) [154]
Homocysteine 1.15 (1.09-1.22) (N = 20, n = 22 652) [155,156]
Coagulation marker:
Fibrinogen 1.15 (1.13-1.17) (N = 40, n = 185 892) [149]
Necrosis marker:
Troponins 1.15 (1.04-1.27) (n = 3 265) [157]
Renal function marker:
Urinary ACR 1.57 (1.26-1.95) (n = 626) [158]
Metabolic markers:
HbA1c 1.42 (1.16-1.74) (N = 2, n = 2 442) [159]
IGF-1 0.76 (0.56-1.04) (n = 3 967) [160]
Adiponectin 0.97 (0.86-1.09) (N = 14, n =21 272) [161]
Cortisol 1.10 (0.97-1.25) (n = 2 512) [162,163]
BDNF ? N/A [71,73,74]
Insulin resistance (HOMA) 1.46 (1.26-1.69) (N = 17, n = 51 161) [164]
Only recent and/or highly cited papers have been cited here. n denotes number of participants; N, number of trials; ?, a possible, though not currently
quantified effect on CHD risk; HDL, high-density lipoprotein; BNP, B-type natriuretic peptide; ACR, albumin–to-creatinine ratio; GDF-15, growth-
differentiation factor-15; LDL, low-density lipoprotein; HbA1c, glycosylated haemoglobin A1c; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6;
TNF-α, tumour necrosis factor-α; ApoB, apolipoprotein-B; IGF-1, insulin-like growth factor-1; MPO, myeloperoxidase; RANKL or OPG, osteoprotegerin; BDNF,
brain-derived neurotrophic factor; HOMA, homeostatic model assessment.
Mathews et al. Nutrition & Metabolism  (2015) 12:6 Page 8 of 15relationship between increased serum insulin levels and
increased fibrinogen levels [130,131,171] and a possible
state of hypercoagulation. Therefore HGL diet induced in-
sulin resistance may have an effect on coagulation, which
is a hallmark of CHD.
It has been found that high carbohydrate diets can
affect changes in lipid profile, regardless of the choles-
terol, protein or fat content [172,173]. Similar trends are
observed in HGL diets which have been found to provide
reductions in HDL levels and increased LDL and triacyl-
glycerol levels [55,174] as shown in Figure 3. These resultssuggest that HGL diets have an attributable effect on the
traditional CHD biomarkers HDL and LDL.
Therefore, it can be seen that HGL diets affect all of
the aforementioned serological biomarkers in such a
manner that the risk for CHD would be increased. The
negative effects of HGL diets on a patient’s risk for CHD
can thus be quantified in a general sense through the
consideration of the connection graph in Figure 3. Fur-
thermore, it is possible to consider patient-specific reac-
tions to HGL diets by measuring said patients biomarker
levels.
Figure 2 Normalised relative risks (fold-change) of salient current and potential biomarkers for CHD. Increased IGF-1 and HDL levels are
associated with a moderately decreased CHD risk. (IGF-1 and HDL levels are significantly inversely correlated to relative risk for CHD.) N indicates
number of trials; I, standard error; Adipo, adiponectin; HDL, high-density lipoprotein; BNP, B-type natriuretic peptide; ACR, albumin-to-creatinine
ratio; GDF-15, growth-differentiation factor-15; Cysteine, Homocysteine; LDL, low-density lipoprotein; HbA1c, glycosylated haemoglobin A1c; Trop,
troponins; Trigl, triglycerides; CRP, C-reactive protein; IL-6, interleukin-6; Fibrin, fibrinogen; Cort, cortisol; TNF-α, tumour necrosis factor-α; ApoB,
apolipoprotein-B; IGF-1, insulin-like growth factor-1; MPO, myeloperoxidase; RANKL or OPG, osteoprotegerin; BDNF, brain-derived neurotrophic factor.
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diets which serve to increase the relative risk for CHD
would be the hyperglycaemia and hyperinsulinaemia that
may result from these diets. Both these factors are also as-
sociated with a greatly increased risk for CHD.
Further potential mediation of CHD risk may also be
due to increased fibrinogen levels as a result of hyperinsu-
linaemia. HGL diets also have adverse impacts on lipids
levels through decreased levels of HDL and increased
levels of LDL, both conditions of which serve to increase
the risk of CHD.
In general, based on a recent meta-analysis of eight studies
where modest heterogeneity was present [175], HGL diets
are associated with an increased RR of 1.36 (95% confidence
interval 1.13 to 1.63). This smaller-than-expected RR ef-
fect can be somewhat explained by the heterogeneity of the
study, i.e. the difference in risk between men and women.
In general, women have been found to have a higher rela-
tive risk for CHD in association with HGL diets [3,175].
Heterogeneity is to be expected in the combined risk for
CHD as some studies have found that there is no increased
risk due to HGL diets in men [176], while other studies have
found no increased risk association with women [177].
Discussion
As can be seen from the preceding discussion, the adoption
of HGL diets can have negative impacts on the pathogenesisof CHD which is evident through the modification of sev-
eral CHD biomarkers. The implication from this is that
an increased risk for CHD is observed with the con-
sumption of HGL diets. It is therefore the opinion of
the authors that modern dietary guidelines for patients at
risk of CHD should reflect this as there is an inadvertent
danger of consuming a HGL diet based on current dietary
guidelines.
The latest AHA dietary guidelines have attempted to
focus on overall diet quality, rather than on specific macro-
nutrient content. Some emphasis was placed on restricting
or increasing the consumption of certain types of foods,
such as increasing high-fibre foods and decreasing
high-trans-fat foods [4]. However, these and previous
guidelines have inadvertently caused the adoption of
high-carbohydrate diets in order to increase fibre intake
and reduce trans-fats [173,178,179] which may lead to
HGL diets.
It is acknowledged that the intent of the AHA guide-
lines was never to increase carbohydrate intake, but in-
stead to increase the intake of fibre through high-fibre
carbohydrates and to decrease the consumption of satu-
rated fats. Unfortunately, many patients opt for foods
that do not meet the required fibre consumption guide-
lines [178] which results in the inherent carbohydrates
imparting a greater GL, which has been negatively asso-
ciated with CHD risk in this paper and others [180].
Figure 3 Interconnection of relative risk effects of high glycemic load diets and serological biomarkers for CHD. “ACR” denotes
albumin-to-creatinine ratio; Trop, troponins; Fibrin, fibrinogen; MPO, myeloperoxidase; BNP, B-type natriuretic peptide; Cysteine, Homocysteine;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; Trigl, triglycerides; ApoB, Apolipoprotein-B; Adipon, adiponectin; HbA1c, glycosylated
haemoglobin A1c; Cort, cortisol; IGF-1, insulin-like growth factor-1; BDNF, brain-derived neurotrophic factor; GDF-15, growth-differentiation
factor-15; CRP, C-reactive protein; IL-6, interleukin-6; TNF-α, tumour necrosis factor-α; RANKL or OPG, osteoprotegerin.
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tions as described by the AHA is the eventual use of
high-carbohydrate content foods. It has been proven that
high- carbohydrate diets have adverse effects on many of
the risk factors which are targeted by the AHA guidelines,
including lipid profiles and blood glucose levels [172,178].
A comparison of three different diets by McAuley and co-
workers showed that the use of the traditional AHA
guideline diet proved to be the worst of the three diets for
mediating the risk factors for CHD [178].
Dietary recommendations have long been focused
on the type of ingested food [4,181]. However, it has
recently become more evident that the type of food
ingested is less important than the overall amount of cal-
ories ingested [173,178]. Therefore, adherence to any low
calorie diet is more important than the specific type of
diet [182].
Thus an easy-to-follow and understand diet is obviously
required in order to adequately address the issue of “heart
healthy” diets and CHD. It is clear from Figure 1 that
there is an abundance of links between the hallmarks of
CHD and hyperglycaemia and insulin resistance fromHGL diets. This was highlighted in the discussion of the
pathways that are activated by HGL diets.
The importance of hyperglycaemia and insulin resist-
ance is further highlighted by the increased risks associ-
ated with each prospective biomarker [159,164]. As the
effects of HGL diets are largely dependent on carbohy-
drate absorption into the blood stream [127], it may be
interesting to consider the effect of inhibiting this ab-
sorption. In the integrated system, in Figure 1, the path-
way representing carbohydrate absorption is pathway-17,
which as indicated can be regulated with the use of α-
glucosidase inhibitors [183].
The α-glucosidase inhibitors thus give some insight
into the effect of reduced carbohydrate consumption, as
would be possible to achieve with a low GL diet. The α-
glucosidase inhibitor acarbose has been successfully
employed to counteract the effects of carbohydrates in
diabetic patients [184,185].
The use of α-glucosidase inhibitors serves to delay the
breakdown of carbohydrates in the gut, which slows
down the absorption of sugars [183]. This reduces
plasma glucose levels, which in turn reduces the
Mathews et al. Nutrition & Metabolism  (2015) 12:6 Page 11 of 15requirement of plasma insulin, both risk factors for
CHD (Figure 2).
If one then considers that the use of acarbose in dia-
betic patients resulted in a much lower incidence of
CHD according to a meta-analysis of seven studies com-
promising 2180 patients. It was found that the RR for
CHD was 0.36 (95% CI 0.16 to 0.80) in diabetic patients
using acarbose compared to the control group [186].
This equates to a 2.78-fold reduction in CHD risk when
using our notation.
This substantial relative risk reduction achieved with
acarbose [186] accentuates the importance of the specific
path on which this pharmacotherapeutic acts (Pathway
17). Through the inhibition of carbohydrate digestion in
the stomach, α-glucosidase inhibitors reduce blood glu-
cose levels (HbA1c) and reduce insulin levels, increasing
insulin sensitivity. Therefore, if α-glucosidase inhibitors
are effective to regulate blood glucose levels and insulin
resistance, then much of the risk reduction can be ex-
plained by the combined effects of decreased blood glu-
cose levels and increased insulin sensitivity [187].
It is important to note that the CHD risk reduction ef-
fects that have been observed from treatment with α-
glucosidase inhibitors were found in studies on patients
with type 2 diabetes mellitus [186]. It is thus conceivable
that the reductions in CHD risk achieved could be
greater than expected due to the increased risk for CHD
associated with type 2 diabetes mellitus [188]. However
the underlying effect of α-glucosidase inhibitors on
blood glucose and insulin levels may retain it as a suit-
able candidate for treatment and prevention of CHD in
non-diabetic patients.
The effectiveness of α-glucosidase inhibitors in redu-
cing CHD risk in diabetic patients clearly elucidates the
importance of the main pathways which they regulate
with regards to CHD. This may therefore indicate the
importance of regulating these pathways in non-diabetic
patients to prevent CHD, such as through the adoption
of low GL diets.
Conclusions
The authors were intrigued by the possible negative effects
of HGL diets on a patient’s risk for CHD as well as the
over emphasis of LDL cholesterol. As LDL is not the only
or even the most important biomarker for CHD risk, a
more detailed integrated view of diet and the CHD mech-
anism as well as its biomarkers were attempted.
The integrative view highlights the increased potential
CHD risk that is associated with HGL diets. This potential
risk is clearly elucidated in the wide range of CHD patho-
genetic pathways which are mediated by HGL diets and
the large array of CHD biomarkers which are affected as
vividly shown in the simplified “connection graph”. HGL
diets do not only influence the lipid and metabolicbiomarkers, but also coagulation and vascular function
biomarkers.
The use of α-glucosidase inhibitors is also found as
substantially beneficial in CHD prevention efforts in dia-
betic patients by controlling important pathways shown
in the integrated view of CHD. This further emphasises
the importance of blood glucose and insulin levels in the
prevention of CHD in diabetic patients. The array of
biomarkers affected by these pharmacotherapeutic inter-
ventions would also indicate that these conditions could
be of importance to non-diabetic patients.
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